Volume 3 Supplement 1

ESICM LIVES 2015

Open Access

Early magnesium treatment after aneurysmal subarachnoid hemorrhage: an individual patient data meta-analysis

  • WM van den Bergh1 and
  • writing groups of MASH-I, IMASH, MASH-II, MASH and FAST-MAG
Intensive Care Medicine Experimental20153(Suppl 1):A774

DOI: 10.1186/2197-425X-3-S1-A774

Published: 1 October 2015

Introduction

Delayed cerebral ischemia (DCI) is an important cause of poor outcome after aneurysmal subarachnoid hemorrhage (SAH). Trials on magnesium treatment starting < 4 days after symptom onset found no effect on poor outcome or DCI in SAH. Earlier instalment of treatment might be more effective, but individual trials had not enough power for such a sub-analysis.

Objectives

We performed an individual patient data meta-analysis to study whether magnesium is effective when given within different time frames within 24 hours after the SAH.

Methods

Patients were divided into categories according to the delay between symptom onset and start of the study medication: < 6 hours, 6-12 hours, 12-24 hours, > 24 hours. We calculated adjusted risk ratios (aRR) with corresponding 95% confidence intervals (CI) for magnesium versus placebo treatment for poor outcome and DCI.

Results

We included 5 trials totalling 1981 patients, 83 patients started treatment < 6 hours. For poor outcome the aRRs of magnesium treatment for start < 6 hours were 1.44 (95%CI:0.83-2.51); for 6-12 hours 1.03(0.65-1.63), for 12-24 hours 0.84(0.65-1.09) and for >24 hours 1.06(0.87-1.31), and for DCI, < 6 hours 1.76(0.68-4.58), for 6-12 hours 2.09(0.99-4.39), for 12-24 hours 0.80(0.56-1.16) and for > 24 hours 1.08(0.88-1.32).

Conclusions

This meta-analysis suggests no beneficial effect of magnesium treatment on poor outcome or DCI when started early after SAH onset. Although the number of patients was small and a beneficial effect cannot be definitively excluded, we found no justification for a new trial with early magnesium treatment after SAH.
https://static-content.springer.com/image/art%3A10.1186%2F2197-425X-3-S1-A774/MediaObjects/40635_2015_Article_915_Fig1_HTML.jpg
Figure 1

Adjusted RR for occurrence of DCI for magnesium ve.

https://static-content.springer.com/image/art%3A10.1186%2F2197-425X-3-S1-A774/MediaObjects/40635_2015_Article_915_Fig2_HTML.jpg
Figure 2

Adjusted RR for poor outcome for magnesium versus.

Authors’ Affiliations

(1)
University Medical Center Groningen, Critical Care

Copyright

© van den Bergh et al.; 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement